Amanda Swearengen is an influential leader recognized for her visionary approach to process design, documentation, and change management in the pharmaceutical arena. As Director II, Strategic Change Enablement at AbbVie, Amanda leads a high-performing team committed to driving innovative change and accelerating adoption to achieve excellence in clinical research processes. She has elevated her team’s impact and capabilities, delivering transformative solutions that streamline operations—from reimagining quality system documentation to deploying end-to-end clinical trial process maps. With an MBA in Project Management and certifications in Lean Six Sigma and Prosci Change Management, Amanda excels at developing talent, cultivating strong partnerships, and nurturing inclusive, future-focused cultures. Her energetic leadership and execution turns bold strategies into tangible results, positioning her as a catalyst for operational agility, innovation, and sustainable change at AbbVie and beyond.
How AbbVie and BusinessOptix are building visibility, agility, and readiness for AI-driven transformation.
AI is reshaping the way organizations approach operational excellence, but real success depends on what comes first: building the foundation. In this fireside chat, Joy Shelledy, Director, Strategic Change Enablement, AbbVie; Amanda Swearengen, Director II, Strategic Change Enablement, AbbVie and Jeff Alker, Solutions Consultant, BusinessOptix, will explore how life sciences leaders can map and model processes to create end-to-end visibility, test scenarios before committing to automation, and establish ROI long before bots or AI are deployed.
The discussion will highlight AbbVie’s journey, in documenting their end-to-end clinical trial processes leveraging the BusinessOptix platform and how this sets them up for the next wave of innovation. Beyond technology, the speakers will address the human side of transformation, including organizational agility, change management and sustaining impact across the enterprise.